Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain
<b>Background:</b> The Spanish Interterritorial Council of the National Health System (a central government body) currently recommends vaccination against meningococcal serogroup C (MenC) at 4 and 12 months of age for prevention of invasive meningococcal disease (IMD). The Advisory Commi...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-06-01
|
| Series: | Vaccines |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-393X/13/6/642 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849433924293361664 |
|---|---|
| author | Katharina Schley Jamie Findlow Carlos Molina Shannon M. Sullivan Eszter Tichy |
| author_facet | Katharina Schley Jamie Findlow Carlos Molina Shannon M. Sullivan Eszter Tichy |
| author_sort | Katharina Schley |
| collection | DOAJ |
| description | <b>Background:</b> The Spanish Interterritorial Council of the National Health System (a central government body) currently recommends vaccination against meningococcal serogroup C (MenC) at 4 and 12 months of age for prevention of invasive meningococcal disease (IMD). The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (a professional medical association) and numerous Spanish regional bodies instead recommend quadrivalent vaccination against serogroups A, C, W, and Y (MenACWY) at 4 and 12 months of age. The central government and Spanish Association of Pediatrics also recommend MenACWY vaccination at 12 years of age. This study assessed the potential public health effects of replacing the MenC vaccination schedule with different MenACWY vaccination schedules in infants. <b>Methods:</b> Here, a static multi-cohort population model was used to evaluate potential effects on public health of IMD due to meningococcal serogroups C/W/Y, comparing MenC infant vaccination (reference strategy) against four different strategies including quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix<sup>®</sup>, Pfizer Europe MA EEIG, Brussels, Belgium) infant vaccination; all strategies included MenACWY-TT vaccination at 12 years of age. <b>Results:</b> The most effective strategy for infant vaccination was MenACWY-TT at 2, 4, and 12 months, preventing an estimated additional 103 IMD cases, 17 deaths, and 41 cases with long-term sequelae (LTS) versus the reference strategy in the base-case IMD incidence scenario. When strategies included a two-dose infant schedule, the earlier the infant MenACWY-TT vaccine was administered, the more additional cases, deaths, and cases with LTS were prevented (base-case and high-incidence scenarios). <b>Conclusions:</b> This analysis supports implementation of MenACWY-TT as a replacement for MenC vaccination. |
| format | Article |
| id | doaj-art-69dc4e8ecedf491ebdce5b21b91e256b |
| institution | Kabale University |
| issn | 2076-393X |
| language | English |
| publishDate | 2025-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Vaccines |
| spelling | doaj-art-69dc4e8ecedf491ebdce5b21b91e256b2025-08-20T03:26:52ZengMDPI AGVaccines2076-393X2025-06-0113664210.3390/vaccines13060642Public Health Impact of Potential Infant MenACWY Vaccination Strategies in SpainKatharina Schley0Jamie Findlow1Carlos Molina2Shannon M. Sullivan3Eszter Tichy4Global Access and Value, Pfizer Pharma GmbH, 10117 Berlin, GermanyPfizer Global Medical Affairs, Vaccines and Antivirals, Pfizer Ltd., Tadworth KT20 7NS, UKMedical Department, Pfizer S.L.U., 28108 Madrid, SpainPPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, 94853 Ivry-sur-Seine Cedex, FrancePPD Evidera Health Economics & Market Access, Thermo Fisher Scientific, H-1113 Budapest, Hungary<b>Background:</b> The Spanish Interterritorial Council of the National Health System (a central government body) currently recommends vaccination against meningococcal serogroup C (MenC) at 4 and 12 months of age for prevention of invasive meningococcal disease (IMD). The Advisory Committee on Vaccines of the Spanish Association of Pediatrics (a professional medical association) and numerous Spanish regional bodies instead recommend quadrivalent vaccination against serogroups A, C, W, and Y (MenACWY) at 4 and 12 months of age. The central government and Spanish Association of Pediatrics also recommend MenACWY vaccination at 12 years of age. This study assessed the potential public health effects of replacing the MenC vaccination schedule with different MenACWY vaccination schedules in infants. <b>Methods:</b> Here, a static multi-cohort population model was used to evaluate potential effects on public health of IMD due to meningococcal serogroups C/W/Y, comparing MenC infant vaccination (reference strategy) against four different strategies including quadrivalent tetanus toxoid conjugate vaccine (MenACWY-TT; Nimenrix<sup>®</sup>, Pfizer Europe MA EEIG, Brussels, Belgium) infant vaccination; all strategies included MenACWY-TT vaccination at 12 years of age. <b>Results:</b> The most effective strategy for infant vaccination was MenACWY-TT at 2, 4, and 12 months, preventing an estimated additional 103 IMD cases, 17 deaths, and 41 cases with long-term sequelae (LTS) versus the reference strategy in the base-case IMD incidence scenario. When strategies included a two-dose infant schedule, the earlier the infant MenACWY-TT vaccine was administered, the more additional cases, deaths, and cases with LTS were prevented (base-case and high-incidence scenarios). <b>Conclusions:</b> This analysis supports implementation of MenACWY-TT as a replacement for MenC vaccination.https://www.mdpi.com/2076-393X/13/6/642immunizationinvasive meningococcal diseasemeningococcal vaccinepublic healthSpainvaccine |
| spellingShingle | Katharina Schley Jamie Findlow Carlos Molina Shannon M. Sullivan Eszter Tichy Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain Vaccines immunization invasive meningococcal disease meningococcal vaccine public health Spain vaccine |
| title | Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain |
| title_full | Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain |
| title_fullStr | Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain |
| title_full_unstemmed | Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain |
| title_short | Public Health Impact of Potential Infant MenACWY Vaccination Strategies in Spain |
| title_sort | public health impact of potential infant menacwy vaccination strategies in spain |
| topic | immunization invasive meningococcal disease meningococcal vaccine public health Spain vaccine |
| url | https://www.mdpi.com/2076-393X/13/6/642 |
| work_keys_str_mv | AT katharinaschley publichealthimpactofpotentialinfantmenacwyvaccinationstrategiesinspain AT jamiefindlow publichealthimpactofpotentialinfantmenacwyvaccinationstrategiesinspain AT carlosmolina publichealthimpactofpotentialinfantmenacwyvaccinationstrategiesinspain AT shannonmsullivan publichealthimpactofpotentialinfantmenacwyvaccinationstrategiesinspain AT esztertichy publichealthimpactofpotentialinfantmenacwyvaccinationstrategiesinspain |